Compare JPMorgan Equity Premium Income ETF (JEPI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs TransMedics Group Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.55B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 16.6× TransMedics Group Inc's market cap, and JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 57 Days and TransMedics Group Inc for 24 Days on average.
| JEPI | TMDX | |
|---|---|---|
Market Cap | $45.55B | $2.74B |
Volume | 3,820,809 | 949,331 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $150.42 |
52-Week Low | $55.29 | $61.99 |
Typical Hold Time | 57 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.77, up 0.57% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend payments with recent distributions of $0.34-$0.37, positioning it as an income-focused vehicle. Recent news highlights JEPI's role in retirement income strategies and its appeal to investors seeking monthly distributions from covered call strategies.
The outlook remains cautious given the bearish technical setup, though the income generation capability provides downside cushion. Key risks include market volatility impacting the covered call strategy and interest rate sensitivity. Institutional interest continues with recent position increases, supporting the ETF's income-oriented appeal in uncertain markets.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
